Bai L, et al. - A Markov model containing three health states (PFS, progressive disease, and death) were used to investigate the cost-efficiency of these two first-line regimens in people with RAS wide-type (wt) metastatic colorectal cancer (mCRC) from the Chinese societal perspective. Sensitivity analysis revealed that in the cetuximab plus fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) arm, the cost of PFS was the most robust factor in the Markov model. Thus, from the viewpoint of Chinese society, for the first-line treatment of an individual with RAS wt mCRC, the combination of cetuximab and FOLFOX-4 is not a cost-efficient approach in comparison with FOLFOX-4 alone.